Two Paths to the Same Active Ingredient
When you receive a GLP-1 prescription in 2026, it will generally come from one of two sources: an FDA-approved brand-name product manufactured by a major pharmaceutical company (Novo Nordisk or Eli Lilly), or a compounded formulation prepared by a compounding pharmacy. Both contain the same active ingredients — semaglutide or tirzepatide — but they differ substantially in regulation, cost, formulation, and quality assurance.
Brand-Name GLP-1 Medications
Brand-name products have undergone the full FDA approval process, including large-scale clinical trials establishing safety and efficacy. In 2026, the available brand-name options include Wegovy and Wegovy HD (semaglutide injections), the Wegovy pill (oral semaglutide), Ozempic (semaglutide for diabetes), Zepbound (tirzepatide injection), Mounjaro (tirzepatide for diabetes), and Foundayo (orforglipron oral tablet). These medications are manufactured under strict Current Good Manufacturing Practice (cGMP) regulations, with every batch tested for potency, purity, and sterility.
The trade-off is cost. Without insurance, brand-name GLP-1s range from $900 to $1,400 per month at retail pharmacy prices. Manufacturer programs have brought this down significantly — Novo Nordisk offers Wegovy starting at $199 to $349 per month through NovoCare, and Eli Lilly offers Foundayo starting at $149 per month through LillyDirect — but these prices are still out of reach for many.
Compounded GLP-1 Medications
Compounded medications are prepared by compounding pharmacies — either 503A (traditional, patient-specific) or 503B (outsourcing facilities that can produce larger batches). These pharmacies take the raw active pharmaceutical ingredient and formulate it into injectable, sublingual, or oral forms.
The primary advantage of compounded GLP-1s is cost. Telehealth platforms offering compounded semaglutide typically charge $149 to $299 per month, and some offer compounded tirzepatide in the $189 to $399 range. These prices include the provider consultation and medication.
503A vs. 503B: A Critical Difference
Not all compounding pharmacies are regulated equally. 503A pharmacies operate under state pharmacy boards and prepare medications for individual patients based on specific prescriptions. They're subject to less federal oversight. 503B outsourcing facilities are FDA-registered, inspected, and required to follow cGMP standards — the same manufacturing quality standards as brand-name drug makers. They also perform mandatory batch testing for potency and sterility.
If you're considering compounded GLP-1 medications, ask your provider which type of pharmacy they use. A 503B outsourcing facility provides a meaningfully higher level of quality assurance.
What the End of the Shortage Means
The FDA declared the semaglutide shortage resolved on February 21, 2025, and the tirzepatide shortage ended on October 2, 2024. During the shortages, compounding pharmacies were broadly permitted to produce copies of these medications under federal law. With the shortages resolved, the legal landscape for compounding has shifted.
Compounding pharmacies can no longer produce formulations that are "essentially a copy" of commercially available FDA-approved products for routine dispensing. However, 503A pharmacies may still legally produce GLP-1 formulations that differ from commercial products — such as different doses, alternative forms (sublingual drops, oral tablets), or combinations with additional ingredients (B12, L-carnitine, NAD+). These require a valid patient-specific prescription with documented medical necessity.
How to Evaluate Your Options
| Factor | Brand-Name | Compounded |
|---|---|---|
| FDA approval | Yes — full clinical trial data | No — not individually reviewed by FDA |
| Monthly cost (self-pay) | $149–$449 via manufacturer programs | $149–$399 via telehealth |
| Insurance coverage | Possible with prior authorization | Generally not covered |
| Quality assurance | cGMP, batch-tested | Varies — 503B is stricter than 503A |
| Formulation options | Fixed FDA-approved forms | Customizable (sublingual, oral, combined) |
| Availability | Retail pharmacies, manufacturer-direct | Telehealth platforms, compounding pharmacies |
What Should You Choose?
There's no universally correct answer. If you have insurance that covers GLP-1s, brand-name medications are the straightforward choice — they come with the highest level of regulatory assurance and your out-of-pocket cost may be as low as $25 per month with a savings card. If you're paying out of pocket, the cost difference between brand-name manufacturer programs and compounded options has narrowed considerably in 2026, making brand-name more accessible than ever.
If you do choose compounded, prioritize providers who work with 503B outsourcing facilities, ask about third-party potency and sterility testing, and verify the pharmacy's FDA registration and any LegitScript certification. Your health is the priority — saving money shouldn't come at the expense of medication quality.